Company Overview and News

2
Should You Invest in the Invesco S&P Global Water Index ETF (CGW)?

2018-09-05 zacks
Launched on 05/14/2007, the Invesco S&P Global Water Index ETF (CGW - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Industrials - Water segment of the equity market.
AWK IEX XYL FIDU

40
5 Utility Stocks to Buy for an Extra Durable Portfolio

2018-09-04 investorplace
The theory regarding utility stocks to buy was simple: Robust economic growth coupled with a full labor market was supposed to spark rising inflation. The Fed was supposed to fight rising inflation with rate hikes. Fixed income yields were supposed to rise. Utility stocks, which were long viewed as bond substitutes in an era of ultra-low interest rates, were supposed to fall.
AWK AMZN SRE AEP NEE

2
Should You Invest in the Invesco S&P Global Water Index ETF (CGW)?

2018-08-13 zacks
If you're interested in broad exposure to the Industrials - Water segment of the equity market, look no further than the Invesco S&P Global Water Index ETF (CGW - Free Report) , a passively managed exchange traded fund launched on 05/14/2007.
FMAT AWK IEX XYL FIDU

2
AWK / American Water Works Co., Inc. FORM 8-K (Current Report)

2018-08-09 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AWK

2
AWK / American Water Works Co., Inc. 424B2 (Prospectus)

2018-08-07 sec.gov
424B2 Table of Contents CALCULATION OF REGISTRATION FEE
AWK

2
AWK / American Water Works Co., Inc. 424B2 (Prospectus)

2018-08-07 sec.gov
424B2 Table of Contents CALCULATION OF REGISTRATION FEE
AWK

2
AWK / American Water Works Co., Inc. FWP

2018-08-06 sec.gov
FWP Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement Nos. 333-224558 and 333-
AWK

2
AWK / American Water Works Co., Inc. FWP

2018-08-06 sec.gov
FWP Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement Nos. 333-224558 and 333-
AWK

2
AWK / American Water Works Co., Inc. 424B5 (Prospectus)

2018-08-06 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) File Number 333-224558-01 File Number 333-224558 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities became automatically effective when
AWK

2
AWK / American Water Works Co., Inc. 424B5 (Prospectus)

2018-08-06 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) File Number 333-224558-01 File Number 333-224558 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities became automatically effective when
AWK

2
American Water Works Company, Inc. (AWK) CEO Susan Story on Q2 2018 Results - Earnings Call Transcript

2018-08-02 seekingalpha
American Water Works Company, Inc. (NYSE:AWK) Q2 2018 Earnings Conference Call August 2, 2018 9:00 AM ET
AWK

2
AWK / American Water Works Co., Inc. 10-Q (Quarterly Report)

2018-08-01 sec.gov
Document Table of Contents
AWK

2
Should You Invest in the Invesco S&P Global Water Index ETF (CGW)?

2018-07-20 zacks
If you're interested in broad exposure to the Industrials - Water segment of the equity market, look no further than the Invesco S&P Global Water Index ETF (CGW - Free Report) , a passively managed exchange traded fund launched on 05/14/2007.
KDP AWK XYL DHR

31
Should You Invest in the Guggenheim S&P Global Water Index ETF (CGW)?

2018-06-27 zacks
Designed to provide broad exposure to the Industrials - Water segment of the U.S. equity market, the Guggenheim S&P Global Water Index ETF (CGW - Free Report) is a passively managed exchange traded fund launched on 05/14/2007.
AWK XYL FIDU ICHR DHR

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to AWK / American Water Works Co., Inc. on message board site Silicon Investor.

2026 TeoTwawKi ... 2032 Darkest Interregnum 2026 TeoTwawKi ... 2032 Darkest Interregnum 2026 TeoTwawKi ... 2032 Darkest Interregnum Blackhawk Network Holdings, Inc (HAWK) Blackhawk Network Holdings, Inc (HAWK) Blackhawk Network Holdings, Inc (HAWK)
HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options
HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD. TSX SYMBOL - HGO HAWKEYE GOLD. TSX SYMBOL - HGO HAWKEYE GOLD. TSX SYMBOL - HGO
NightHawk Radiology NightHawk Radiology NightHawk Radiology BHWF -- The BlackHawk Fund BHWF -- The BlackHawk Fund BHWF -- The BlackHawk Fund
CNBC-Squawk Box Trading CNBC-Squawk Box Trading CNBC-Squawk Box Trading HAWKEYE GOLD INTERNATIONAL INC. HAWKEYE GOLD INTERNATIONAL INC. HAWKEYE GOLD INTERNATIONAL INC.
CUSIP: 030420103